AGM 2020 Presentation

November 18, 2020August 16, 2022 Alterity Therapeutics

2020

Post navigation

Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder
Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023
Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy
Appendix 4C – Q3 FY23 Quarterly Cash Flow Report
Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

AGM 2020 Presentation

Related Posts

Prana receives $3 million R&D Tax Incentive Refund

Prana commences research collaboration with Takeda for the treatment of Parkinson’s disease gastrointestinal neuropathology

Notice of General Meeting 2019